October 2013 | Volume 12 | Issue 10 | Supplement | s146 | Copyright © 2013
Kenneth R. Beer MD FAAD and Michael S. Beer
No abstract available
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
The treatment of basal cell carcinoma (BCC) has remained largely unchanged for the past 50 years. Recently, the use of immunomodulators such as imiquimod have been used to treat early lesions. However, the treatment of inoperable BCC did not evolve significantly until the advent of vismodegib. This drug inhibits the hedgehog pathway, which is often defective in BCC, and the United States Food and Drug Administration has approved vismodegib to treat BCC that is locally advanced or metastatic. The use of this drug requires physicians to have an understanding of where it is and where it is not applicable, how the drug works, and which adverse events are associated with it. This supplement details one case of locally advanced BCC and provides information on the therapeutic decisions made for the patient detailed. In addition, information about the mechanisms of action for vismodegib and the burden of disease imposed by advanced or metastatic BCC are provided to help clinicians gain an understanding of the true burden of this disease.
Kenneth R. Beer MD FAADa and Michael S. Beer
aPalm Beach Plastic Surgery Center
West Palm Beach, FL